Black men twice as likely to die from prostate cancer compared to white men
the ONA take:
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men, according to an English population study published in BMC Medicine.
Additionally, Asian men are half as likely to be diagnosed, or die from, prostate cancer in their lifetime compared to white men.
Researchers led by Alison Cooper of Prostate Cancer UK and Public Health England studied prostate cancer incidence and mortality data in England from 2008 to 2010 from a variety of sources, including Public Health England and the Office for National Statistics. In total, their sample size included 25,635,649 men, with 102,252 prostate cancer diagnoses and 26,521 deaths as a result of prostate cancer.
They found that lifetime risk of being diagnosed with prostate cancer in England was about 1 in 8 (13.3 percent) for white men, 1 in 4 (29.3 percent) for black men, and 1 in 13 (7.9 percent) for Asian men.
Risk of dying from prostate cancer in England was found to be about 1 in 24 (4.2 percent) in white men, 1 in 12 (8.7 percent) in black men, and 1 in 44 (2.3 percent) in Asian men.
Independent of ethnicity, white, black and Asian men with prostate cancer diagnosis were found to have a one third chance of dying from the disease.
Further work is needed to understand the mechanisms for the higher risk found in black men.
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|